|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Nat Genet:单基因突变导致过敏性皮炎的发生显示文摘最近,研究者们鉴定出了一类导致神经性皮炎发生的关键基因突变:CARDll。来自美国NIH过敏与传染病研究所的研究者们通过对四个没有血缘关系的患病家庭进行分析,发现了这一导致疾病产生的基因、 | Chi A Ma, Yuan Zhang, Michael A Weinreich, Jonathan J Lyons, Celeste G Nelson, Thomas DiMaggio, Kelly D Stone, Joshua D Milner Jeffrey R Stinson, Elisa Ruffo, Batsukh Dorjbal, Swadhinya Arjunaraja, Kelsey Voss, Andrew L Snow Jordan K Abbott, Pia J Hauk, Paul R Reynolds, Erwin W Gelfand Elisa Ruffo Salomé Glauzy, Natsuko Yamakawa, Eric Meffre Jennifer Stoddard, Julie Niemela, Sergio D Rosenzweig Yu Zhang, Helen F Matthews Joshua J McElwee Nina Jones Alejandro Palma, Matías Oleastro, Emma Prieto, Andrea R Bernasconi, Geronimo Dubra, Silvia Danielian, Jonathan Zaiat, Marcelo A Marti Brian Kim Megan A Cooper Neil Romberg | 2017 | 现代生物医学进展2017，17，27： | 3 |
| 2 | Mechanical Initiation of Intervertebral Disc Degeneration显示文摘 | Michael A. Adams Brian J. C. Freeman Helen P. Morrison Ian W. Nelson Patricia Dolan | 2000 | Spine2000，，13： | 2 |
| 3 | Beyond Philanthropy:Community Enterprise as a Basis for Corporate Citizenship显示文摘 | Paul T Nelson P Helen H | 2005 | Journal of Business Ethics2005，，4： | 1 |
| 4 | Beyond Philanthropy: Community Enterprise as a Basis for Corporate Citizenship显示文摘 | Paul Tracey Nelson Phillips Helen Haugh | 2005 | Journal of Business Ethics2005，，： | 1 |
| 5 | Determination of Elemental Sulfur in Environmental Samples by Gas Chromatography-Mass Spectrometry显示文摘 | Chen Y W Helen A J Nelson B | 1997 | Chemical Geology1997，137，： | 1 |
| 6 | To have and to hold:the bond between older people and the homes they own 显示文摘 | Janet Askham Helen Nelson Anthea Tinker | 1999 | Joseph Rowntree Foundation1999，，57： | 1 |
| 7 | BeyondPhilanthropy: Community Enterprise as a Basis for Corporate Citizenship 显示文摘 | Paul Traeey Nelson Phillips Helen Haugh | 2005 | Journal of Business Ethics2005，，2005： | 1 |
| 8 | To Have and to Hold:the Bond between Older People and the Homes They Own显示文摘 | Janet Askham Helen Nelson Anthea Tinker Ruth Hancock | | 0，，： | 1 |
| 9 | How Policy Positions Women Entrepreneurs: A Comparative Analysis of State Discourse in Sweden and the United States显示文摘 | Helene Ahl & Teresa Nelson | 2015 | Journal of Business Venturing2015，，2： | 1 |
| 10 | High Level of Pyrethroid re sistance in an Anopheles funestus population of the Chokwe Dis trict in Mozambique 显示文摘 | Nelson C John CM Helen I | 2010 | PLoSONE2010，5，11： | 1 |
| 11 | High Level of Pyrethroid Resistance in an Anopheles funestus Population of the Chokwe District in Mozambique显示文摘 | Nelson C John CM Helen I | 2010 | PLoS ONE2010，5，11： | 1 |
| 12 | Homeopathy for COVID-19 in primary care:A randomized,double-blind,placebo-controlled trial(COVID-Simile study)显示文摘Background:Different homeopathic approaches have been used as supportive care for coronavirus disease 2019(COVID-19)cases,but none has been tested in a clinical trial.Objectives:To investigate the effectiveness and safety of the homeopathic medicine,Natrum muriaticum LM2,for mild cases of COVID-19.Design,setting,participants,and interventions:A randomized,double-blind,two-armed,parallel,singlecenter,placebo-controlled clinical trial was conducted from June 2020 to April 2021 in S?o-Carlos,Brazil.Participants aged>18 years,with influenza-like symptoms and positive result from a real-time polymerase chain reaction test for severe acute respiratory syndrome coronavirus 2 were recruited and randomized(1:1)into two groups that received different treatments during a period of at-homeisolation.One group received the homeopathic medicine Natrum muriaticum,prepared with the second degree of the fifty-millesimal dynamization(LM2;Natrum muriaticum LM2),while the other group received a placebo.Outcome measures:The primary endpoint was time until recovery from COVID-19 influenza-like symptoms.Secondary measures included a survival analysis of the number and severity of COVID-19 symptoms(influenza-like symptoms plus anosmia and ageusia)from a symptom grading scale that was informed by the participant,hospital admissions,and adverse events.Kaplan-Meier curves were used to estimate time-to-event(survival)measures.Results:Data from 86 participants were analyzed(homeopathy,n=42;placebo,n=44).There was no difference in time to recovery between two groups among participants who were reporting influenzalike symptoms at the beginning of monitoring(homeopathy,n=41;placebo,n=41;P=0.56),nor in a sub-group that had at least 5 moderate to severe influenza-like symptoms at the beginning of monitoring(homeopathy,n=15;placebo,n=17;P=0.06).Secondary outcomes indicated that a 50%reduction in symptom score was achieved significantly earlier in the homeopathy group(homeopathy,n=24;placebo,n=25;P=0.04),among the participants with a basal symptom score≥5.Moreover,values of restricted mean survival time indicated that patients receiving homeopathy might have improved0.9 days faster during the first five days of follow-up(P=0.022).Hospitalization rates were 2.4%in the homeopathy group and 6.8%in the placebo group(P=0.62).Participants reported 3 adverse events in the homeopathy group and 6 in the placebo group.Conclusion:Results showed that Natrum muriaticum LM2 was safe to use for COVID-19,but there was no statistically significant difference in the primary endpoints of Natrum muriaticum LM2 and placebo for mild COVID-19 cases.Although some secondary measures do not support the null hypothesis,the wide confidence intervals suggest that further studies with larger sample sizes and more symptomatic participants are needed to test the effectiveness of homeopathic Natrum muriaticum LM2 for COVID-19.Trial registration:UMIN Clinical Trials Registry ID:JPRN-UMIN000040602. | Ubiratan Cardinalli Adler Maristela Schiabel Adler Ana Elisa Madureira Padula Livia Mitchiguian Hotta Amarilysde Toledo Cesar JoséNelson Martins Diniz Helen de Freitas Santos Edson Zangiacomi Martinez | 2022 | Journal of Integrative Medicine2022，20，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员